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Aims/hypothesis: Cyclophilin A, an immunophilin is secreted from human monocytes activated by high glucose.
Given its role as an inflammatory mediator of vascular tissue damage associated with inflammation and oxidative
stress, we examined plasma levels of cyclophilin A in normal healthy volunteers and patients with type 2 diabetes
(DM), with or without coronary artery disease (CAD).
Methods: Study subjects comprised of 212 patients with DM and CAD,101 patients with diabetes, 122 patients
with CAD and 121 normal healthy volunteers. Diabetes was assessed by HbA1c levels while coronary artery disease
was established by a positive treadmill test and/or coronary angiography. Plasma cyclophilin A was measured using
a cyclophilin A ELISA Kit. Relationship of plasma cyclophilin A levels with blood markers of type 2 diabetes, blood
lipid levels and medication for diabetes and coronary artery disease were also explored.
Results: Plasma Cyclophilin levels were higher in diabetes patients with or without CAD compared to normal
subjects (P < 0.001). Age, fasting blood sugar levels and HbA1C levels were positively associated with increased
plasma cyclophilin. Patients using metformin had reduced levels of plasma cyclophilin (p < 0.001).Serum levels of
total cholesterol, LDL cholesterol and triglycerides had no significant association with plasma cyclophilin levels. In
patients with increased serum CRP levels, plasma cyclophilin A was also elevated (p = 0.016). Prevalence odds for
DM, DM + CAD and CAD are higher in those with high cyclophilin values, compared to those with lower values,
after adjusting for age and sex, indicating strong association of high cyclophilin values with diabetes and vascular
disease.
Conclusions/interpretations: Our study demonstrates that patients with type 2 diabetes have higher circulating
levels of cyclophilin A than the normal population. Plasma cyclophilin levels were increased in patients with
diabetes and coronary artery disease suggesting a role of this protein in accelerating vascular disease in type
2 diabetes. Considering the evidence that Cyclophilin A is an inflammatory mediator in atherogenesis, the
mechanistic role of cyclophilin A in diabetic vascular disease progression deserves detailed investigation.
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Cyclophilin A is part of various intracellular functions,
such as intracellular signaling, protein trafficking, and
regulating activity of other proteins [1]. Cyclophilin A, is
also well recognized as a secreted growth factor that is
induced by oxidative stress [2] functioning as a mediator
of tissue damage associated with inflammation and oxi-
dative stress [3]. The secretory nature of this protein and
its presence in plasma of patients with DM and CAD
underlines its potential as a marker of disease. We earl-
ier reported proteomic changes occurring in circulating
monocytes on activation with high glucose. We also
demonstrated secretion of cyclophilin A from monocytes
under hyperglycemic conditions. Preliminary studies on
a small number of patients with type 2 diabetes mellitus
and coronary artery disease revealed increased plasma
levels of cyclophilin A compared to normal healthy indi-
viduals [4].
We report here the results of an enzyme linked im-
munosorbent assay based study in a larger study popula-
tion comprising 556 subjects, consisting of patients with
type 2 diabetes mellitus with or without coronary artery
disease, patients with only coronary artery disease and
normal healthy volunteers. Levels of plasma cyclophilin
A in these study groups was determined and correlated




The study was done on patients with type 2 diabetes with
or without macrovascular complications such as coronary
artery disease. Patients were recruited from three multi-
specialty hospital centers in Southern India. All the proto-
cols were submitted to and approved by the Human
Ethics Committee of Rajiv Gandhi Centre for Biotech-
nology and participating hospitals (Indian Institute of
Diabetes, PRS Hospital and Madras Medical Mission). A
written informed consent was obtained from all study sub-
jects. All patients subsequently underwent a standardized
clinical and laboratory evaluation.
The study subjects (n = 556) were divided into five
groups: (i) Patients with type 2 diabetes mellitus (DM; n =
101), (ii) diabetes patients with coronary artery disease
(DM+CAD) diagnosed within 5 years of detection of type
2 diabetes (n = 103), (iii) patients with DM who had CAD
diagnosed five years after detection of diabetes (n = 109),
(iv) patients with CAD (n = 122) and without diabetes and
(v) normal healthy volunteers (n = 121).
Patients with hypertension, cardiac diseases other than
coronary artery disease, peripheral vascular disease,
thrombotic stroke, nephropathy, retinopathy, inflam-
matory disease of any cause, subjects with other sys-
temic and metabolic diseases, asthma, malignancy, liverdiseases, kidney diseases and pregnant women were
excluded from the study. Diabetes was assessed by re-
cording HbA1c and/or fasting blood sugar (FBS) levels
while CAD was diagnosed by a positive treadmill test
and/or coronary angiography.
Enzyme linked assay for measurement of cyclophilin A in
plasma
Blood samples were collected after overnight fasting.
Blood was collected into EDTA containing tubes and
centrifuged for 7 minutes at 2500 g within 30 minutes of
collection. The separated plasma was transferred to a
fresh tube and used directly for the immunoassay as per
the supplier’s protocol. Cyclophilin A levels in plasma
were determined with a sandwich immunoassay kit (Uscn
Life Science Inc, Product No. SEA979Hu). The linearity
of the kit was assayed by testing samples spiked with a
known concentration of cyclophilin A and their serial
dilutions. Spiking with known concentrations of the
protein guaranteed a recovery range of 83–102%. No
significant cross-reactivity or interference with any
other proteins was observed. All samples were analyzed
in duplicate. To maintain assay precision, samples with
a CV > 12% were excluded.
C-Reactive Protein (CRP) was measured with a quan-
tikine sandwich Human CRP Immunoassay (R & D Sys-
tems, Product No: DCRP00). A 93-100% recovery range
was observed when samples were spiked with 1:2 to 1:16
concentrations of CRP.
Medication history was recorded for 270 subjects of the
556 subjects. Medications were grouped into (i) antiplate-
let aggregating agents (Ecospirin, Clopidogrel, Cilostazol),
(ii) Antihypertensive agents (Calcium channel blockers,
ACE inhibitors, vasodilators), (iii) Statins (atorvastatin,
Lovastatin) and (iv) Metformin derivatives (glucophage,
glycimet).
Statistical analysis
The distribution of all variables in the five groups was
studied by describing the mean, median, range and stand-
ard deviation. Predictor variables such as age, HbA1C,
fasting blood sugar (FBS) were grouped into two based on
median values; cyclophilin A levels in the two groups
compared using student t test. The same procedure was
used for comparing cyclophilin levels in groups with dif-
ferent levels of CRP, and in patients using metformin or
not. Cyclophilin values in the five groups were compared
with ANOVA (F = 54.75, p < 0.001), followed by multiple
comparisons using pairwise t tests with pooled variance by
the Holms’ method. We did a multinomial logistic regres-
sion analysis for estimating the prevalence odds ratios for
presence of disease, with the normal subjects as the re-
ference. The odds for prevalence of the other four condi-
tions, i.e., diabetes and no heart disease (DM), heart
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ease of up to 5 years duration (DM + CAD 5Y), and dia-
betes and heart disease beyond 5 years but below
10 years (DM + CAD 10Y), among those subjects with
high cyclophilin levels were compared with prevalence
odds in those with low cyclophilin values, adjusted for
age and sex. All statistical tests were done with an esti-
mated power =0.80. All statistical tests were done in R
(R Core Team , 2013, R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria.); graphs were also created
in R.
Results
Baseline clinical parameters of patients with diabetes,
coronary artery disease and controls
A total of 313 diabetes patients; 212 with CAD and 101
without CAD (210 men and 103 women), 122 patients
with only coronary artery disease (102 men and 20
women) and 121 normal healthy volunteers (66 menTable 1 Frequencies of baseline clinical parameters of the stu
Normal N (%) DM N (%) C
Age
>45 47 (38.8) 18 (18)
<45 74 (61.1) 83 (83) 1
Gender
Male 66 (54.5) 49 (49) 1
Female 55 (48.4) 52 (52)
FBS (mg/dL)
70-110 89 (73.5) 26 (26)
>110 32 (26.4) 75 (75)
HbA1C (%)
<5.7 88 (72.7) 4 (4)
5.7-6.4 28 (23.1) 6 (6) 4
>6.5 5 (4.1) 91 (91)
Total cholesterol (mg/dL)
<200 64 (52.8) 58 (58)
200-240 37 (30.5) 36 (36)
>240 20 (16.5) 7 (7) 1
LDL (mg/dL)
<100 91 (75.2) 33 (33)
>100 30 (24.7) 68 (68)
HDL (mg/dL)
<60 113 (43.3) 90 (90) 1
>60 8 (6.6) 11 (11)
Triglycerides (mg/dL)
<150 113 (43.3) 90 (90)
>150 8 (6.6) 11 (11)and 55 women) without any evidence of systemic dis-
ease participated in the study. The distribution of study
subjects and their baseline clinical characteristics are
described in Table 1. The mean values and standard de-
viation of each clinical parameter is given in Table 2.
Mean HbA1c values were highest in the diabetes melli-
tus (DM) group (mean: 8.3; Std dev: 1.3) followed by the
group of patients with diabetes and coronary artery dis-
ease (DM + CAD10y) (mean: 8.6, Std dev: 2.0). Trigly-
ceride levels were higher in patients with coronary
artery disease irrespective of whether they had diabetes
compared to normal subjects and patients with only
diabetes.
Levels of plasma cyclophilin A and association with
disease
Plasma cyclophilin in the 556 subjects ranged from
5.9 ng/ml to 59.2 ng/ml) with a median value of 16.7
ng/ml. Subjects were divided into two groups: subjects
with plasma cyclophilin <16.7 ng/ml and those abovedy groups
AD N (%) DM+CAD (0-5y) N (%) DM+CAD (5-10y) N (%)
13 (10.6) 6 (5.9) 3 (2.8)
09 (85.3) 97 (95.1) 106 (97.2)
02 (83.6) 83 (81.4) 78 (71.6)
20 (16.3) 20 (19.6) 3 (28.4)
43 (35.2) 25 (24.5) 21 (19.3)
79 (64.7) 78 (76.5) 88 (80.7)
50 (40.9) 1 (1) 3 (2.8)
0 (32.70 19 (18.6) 5 (4.6)
32 (26.2) 83 (81.4) 101 (92.7)
90 (73.7) 78 (76.5) 80 (73.4)
15 (72.2) 12 (11.8) 13 (11.9)
7 ( (13.9) 13 (12.7) 16 (14.7)
78 (63.9) 68 (66.7) 64 (58.7)
44 (36.1) 35 (34.3) 45 (41.3)
17 (95.9) 100 (98) 104 (95.4)
5 (4.1) 3 (2.9) 5 (4.6)
78 (63.9) 64 (62.7) 77 (70.6)
44 (36.1) 39 (38.2) 32 (29.4)
Table 2 Mean values of clinical parameters in the study groups
N DM CAD DM+CAD 5y DM+CAD 10y
M SD M SD M SD M SD M SD
Age 41.6 11.2 55.2 10.0 58.9 11.2 58.8 9.0 62.4 8.4
FBS 106.6 25.8 149.8 54.6 124.8 31.4 145.6 52.8 162 58.1
HbA1c 5.3 0.5 8.3 1.3 6.0 1.1 7.7 1.6 8.6 2.0
Total cholesterol 199 42 192.9 34.5 167.7 56.2 172.1 60.6 170.5 56.0
LDL 92.1 23.9 110.6 22.5 102 36.6 96.9 40.2 105.5 39.3
HDL 43.5 8.5 47.4 9.2 42.4 12.0 36.1 10.1 38.6 11.7
Triglycerides 107.4 29.6 103.2 33.2 136.6 49.0 152.9 81.5 134.4 58.4
Cyclophilin A 13.2 3.8 16.1 4.0 20.0 8.0 18.7 9.4 19.3 8.2
Mean values of clinical parameters in the study groups. N = Normal, DM = Diabetes mellitus, CAD = Coronary artery disease, DM+CAD5y = diabetes patients with
coronary artery disease (DM+CAD) diagnosed within 5 years of detection of type 2 diabetes, DM+CAD10y = patients with DM who had CAD diagnosed five years
after detection of diabetes; M = Median values and SD = Standard deviation.
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cyclophilin levels between males and females (p = 0.72).
We observed that only age (t = 3.93; p < 0.01), FBS (t =
6.19; p < 0.01) and HbA1C (t = 2.34; p = 0.019) were associ-
ated with changes in plasma cyclophilin A levels (Figure 1).
Other variables such as serum levels of total cholesterol,
LDL cholesterol and triglycerides had no significant associ-
ation with plasma cyclophilin levels. Figure 2 describes the
distribution of cyclophilin levels among the various study
groups. The plasma levels of cyclophilin A were signi-
ficantly higher in patients with type 2 diabetes (DM)
in comparison to normal volunteers (p < 0.001). Plasma
levels were of normal distribution in the control group
whereas in other groups the distribution was skewed. We
used ANOVA to look into the association of cyclophilin A
levels in 5 groups of subjects: (i) patients with diabetes
(DM) and diagnosed to have CAD within 5 years of onsetFigure 1 Box and whisker plot of association between (A) HbA1C (B) Ag
HbAlc was divided into <6.4 and 6.4 and above age was divided into <46 andof diabetes (DM+CAD5y), (ii) patients with DM and diag-
nosed to have CAD after 5 years and within 10 years of on-
set of diabetes (DM+CAD 10y), (iii) patients with only
diabetes, (iv) patients with only diabetes, and (v) controls.
The analysis revealed that the normal group (N) was differ-
ent from all other groups, and the diabetic group (DM)
was different from all other groups. The CAD group did
not differ from the DM+CAD groups (both DM+CAD5y
and DM+CAD10y) with respect to cyclophilin levels, but
were distinctly different from normal (N) as well as dia-
betes patient (DM) group.
Multinomial logistic regression analysis revealed that
prevalence odds for all four conditions (DM, DM+CAD
5Y, DM + CAD 10y and CAD) are higher in those with
high cyclophilin values, compared to those with lower
values, after adjusting for age and sex, indicating strong
association of high cyclophilin values with diabetes ande and (C) Fasting blood sugar (FBS) and plasma cyclophilin levels.
>45 and FBS between 70-110 mg/dL and >110 mg/dL.
Figure 2 Box and whisker plot of distribution of cyclophilin levels in plasma of the various study groups. Nt = Normal control; CAD = Coronary
artery disease; DM = Diabetes Mellitus, DM+CAD5y = diabetes patient diagnosed with CAD in 5 years and DM+CAD1Oy = diabetes patients diagnosed
with CAD within 10 years. P values were <0.001 for all groups.
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with both diabetes and heart disease were lower com-
pared to those subjects who had only heart disease; the
last mentioned group had the strongest association with
high cyclophilin values. The prevalence odds ratios and
95% confidence interval are given in Table 3.Association of C reactive protein with cyclophilin A levels
It is well recognized that patients with low serum CRP
(<1 mg/L) are at low risk and those with higher CRP
(>1 mg/L) are at moderate or high risk for future cardio-
vascular events [5]. We evaluated the plasma levels of
cyclophilin A among patients with high and low levels of
CRP. Plasma cyclophilin A levels in patients with higher
serum CRP (>1.4 mg/L, n = 38) and lower serum CRP
(<1.4 mg/L, n = 39) are shown as box-and-whisker plots
in Figure 3. There was a positive association between
higher serum CRP levels and higher plasma cyclophilin
A levels (P = 0.016) compared with plasma cyclophilin
levels in the low serum CRP group.Table 3 Prevalence Odds Ratios (POR) and 95%
confidence intervals for association of disease conditions
with high vs low cyclophilin levels, adjusted for age and
sex, using multinomial logistic regression analysis
Groups* Prevalence odds ratio 95% CI on POR
DM (n=101) 2.37 1.26-4.44
DM+CAD 5Y (n=103) 2.99 1.56-5.71
DM+CAD 10Y (n=109) 3.76 1.97-7.17
CAD (n=122) 5.17 2.76-9.71
*Normal subjects were the referent group. DM = subjects with diabetes only;
DM+CAD 5Y = subjects with diabetes and coronary disease of < 5 years’
duration; DM+10Y = subjects with diabetes and coronary disease with
duration <10 years but > 5years.Cyclophilin levels and medication
Cyclophilin levels were positively associated with use of
metformin (Table 4). The plasma levels of cyclophilin
were low in those regularly taking metformin (p < 0.001).
None of the other medications were found to be associ-
ated with plasma cyclophilin A levels.Discussion
We describe here the difference in circulating levels of
plasma Cyclophilin A in patients with diabetes in com-
parison to normal individuals without any systemic
disease. We used an ELISA method to quantify the
cyclophilin A levels in human plasma. The method is ac-
curate and specific for detection of the immunophilin in
plasma. Cyclophilin A was considerably high in the
plasma of patients with type 2 diabetes. The levels wereFigure 3 Box and whisker plot of correlation between hsCRP
levels and plasma cyclophilin levels. hsCRP levels of patients were
grouped into <1.4 mg/I (low risk) and 1.4 mg/I and above (high risk).
Table 4 Association of medications for diabetes, coronary artery disease and plasma levels of cyclophilin
Medication* Mean Median Std Dev Min range Max range T value P value
(i) Antiplatelets
Yes 15.31 15.58 3.2 9.03 5.54 1.52 0.12
No 14.67 15.12 3.6 5.54 19.93
(ii) Statins
Yes 15.25 15.58 3.3 9.03 22.73 1.28 0.20
No 14.71 15.38 3.5 5.54 19.93
(iii) Antihypertensive
Yes 15.14 15.54 3.3 6.92 22.73 0.84 0.40
No 14.78 15.4 3.5 5.54 19.93
(iv) Metformin
Yes 15.75 16.58 3.2 10.28 22.73 4.00 <0.001
No 14.1 14.33 3.5 5.54 19.92
*Medications were grouped into (i) antiplatelet aggregating agents (Ecospirin, Clopidogrel, Cilostazol) (ii) Statins (atorvastatin, lovastatin) (iii) Antihypertensive
agents (Calcium channel blockers, ACE inhibitors, vasodilators and (iv) metformin derivatives (Glucophage, glycimet).
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coronary artery disease.Cyclophilin as an oxidative stress induced secretory factor
Cyclophilin A has been demonstrated to be an important
secreted oxidative stress induced factor [6]. Cyclophilin A
is secreted from vascular smooth muscle cells (VSMCs)
[7] and endothelial cells (EC) [8] in response to reactive
oxygen species (ROS). Cyclophilin A also stimulates
smooth muscle cell migration and proliferation, endothe-
lial cell adhesion molecule expression and chemotaxis of
inflammatory cells. Studies on cyclophilin knockout mice
models have demonstrated increased atherosclerotic po-
tential clearly indicating its role in vascular disease pro-
gression [6]. Elevated levels of extracellular cyclophilin
have also been detected in the synovial fluid of patients
with rheumatoid arthritis [9]. Studies have reported an
interaction between extracellular cyclophilin and CD 147
expressed by macrophages which may be responsible for
development of arthritis [10]. Cyclophilin A has been
shown to elicit inflammatory responses and thus contrib-
ute to recruitment of circulating blood cells during inflam-
matory response. Secreted cyclophilin A also contributes
to maintaining blood brain barrier integrity and reducing
tissue damage following brain injury. It reduces brain per-
meability by activating survival and growth pathways. Se-
creted cyclophilin A activates endothelial cells, a major
component of blood brain barrier which in turns contrib-
utes to recruitment of circulatory monocytes to aid in
blood brain barrier repair [11]. Given that cyclophilin A is
a potent chemotactic agent for immune cells, particularly
monocytes; it is plausible that this immunophilin plays an
important role in accelerating atherosclerosis in type 2
diabetes.Apart from its secretory features, cyclophilin has also
gained recognition from a methodological point of view.
As diabetes can modulate heart glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) content expres-
sion, data can be normalized to cyclophilin expression
[12]. Moreover, target gene expression may be calcu-
lated by using the expression of the cyclophilin house-
keeping gene as an internal standard [13].
Plasma cyclophilin A levels in diabetes and coronary
artery disease
We had earlier reported that high glucose induces secre-
tion of cyclophilin A from monocytes [4]. We also ob-
served a decrease in expression of this protein in the
monocytes of patients with diabetes mellitus when com-
pared to its expression in healthy controls [4]. Hypergly-
caemia in diabetes and related oxidative stress could
contribute to secretion of cyclophilin A from circulating
monocytes and a rise in plasma cyclophilin A levels as
seen in our patients with diabetes. Plasma cyclophilin
levels have been assessed earlier in patients with coron-
ary artery disease to study the severity of CAD using an
immunoassay similar to the one we employed in our
present study [14]. Satoh et al. divided cyclophilin values
into equal quartiles for their analysis. A positive correl-
ation was noted between plasma cyclophilin levels and
coronary stenosis. Higher quartiles of plasma cyclophilin
levels were associated with the need for coronary inter-
vention. We also observed that patients with CAD, irre-
spective of whether they had diabetes had significantly
higher cyclophilin A levels than those without CAD.
This indicates the possible role of cyclophilin A in the
pathogenesis of vascular disease. We had divided the pa-
tients into two groups based on when CAD was detected
in them. This was done to evaluate whether cyclophilin
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Interestingly cyclophilin A levels were higher in chronic
diabetes with CAD group. The significance of this find-
ing needs to be evaluated through a prospective study.
The high prevalence of diabetes with and without cor-
onary artery disease in those with high blood cyclophilin
levels revealed in multinomial logistic regression analysis
indicate a strong association of high plasma cyclophilin
values with diabetes and vascular disease. The lower de-
gree of association of high plasma cyclophilin levels with
diabetes compared to those patients with only coronary
artery disease could perhaps be explained by the possible
higher mortality and lower survival among with those
with multiple disease, resulting in lower prevalence.
Our study also demonstrates that classical risk factors
and markers of diabetes, such as age, fasting blood sugar
(FBS) and glycated hemoglobin (HbA1c) were positively
associated with plasma cyclophilin levels indicating a spe-
cific relation of plasma cyclophilin levels with hypergly-
cemia. Other parameters such as gender, family history of
diabetes, serum levels of high and low density lipoproteins
and triglycerides were not associated with increase in
cyclophilin levels. Satoh et al. also found that age, diabetes
and hsCRP correlate with plasma cyclophilin levels in their
patients with stenotic coronary arteries [14].
Plasma cyclophilin A is associated with C reactive protein
levels
We next considered the correlation between plasma
cyclophilin A and serum C reactive protein (CRP), a
clinical marker of vascular inflammation [5]. CRP, an
acute phase reactant has been developed as a surrogate
marker of inflammatory mediators in coronary artery
disease and diabetes [15–18]. The classical prospective
study by Ridker et al. found elevated CRP to be an inde-
pendent risk determinant of type 2 diabetes in healthy
middle aged women [19]. CRP levels are observed to be
higher in many diseases such as infections, trauma, or
malignancy, as well as inflammatory, allergic, or necrotic
diseases [20]. We evaluated the role of cyclophilin A
among patients with high and low levels of serum CRP.
We had looked into serum levels of CRP in a small lim-
ited subset of 77 individuals. Patients with low CRP
(<1 mg/L) are at low risk and those with higher CRP
(>1 mg/L) are at moderate or high risk for future car-
diovascular events. We observed a positive correlation
between plasma cyclophilin A and serum CRP levels.
There was a positive association between patients with
higher hsCRP levels and those with elevated plasma
cyclophilin A in patients with diabetes as well as those
with diabetes and CAD. Correlation (Pearson) Co-efficients
of cyclophilin values were however, not significant between
CRP and cyclophilin values possibly due to limited sample
subset. A study by Satoh et al. [14] had suggested the useof cyclophilin A in conjunction with CRP as a predictor of
risk in coronary artery disease in a study comprising of
320 patients with CAD. These findings suggest the pos-
sible utility of plasma cyclophilin A level as a marker of
proinflammatory status in patients with diabetes.Metformin may reduce plasma cyclophilin levels
To understand the variation in cyclophilin levels in rela-
tion to use of medication for diabetes and coronary ar-
tery disease, we looked into the association of plasma
cyclophilin levels with the intake of medicines prescribed
for these diseases. Cardiovascular drugs such as aspirin,
clopidogrel and statins did not have any effect on plasma
cyclophilin levels, whereas metformin intake was associ-
ated with decreased plasma cyclophilin levels. Metformin
is a standard hypoglycemic drug used in treatment of
non-insulin dependent diabetes mellitus [21]. The action
of this drug is at the skeletal muscle, increasing glucose
transport across the cell membrane [22]. Metformin is also
known to reduce gene expression of inflammatory media-
tors such as IL-1 and Monocyte chemoattractant protein
(MCP)-1 [23]. Metformin also reduces gene expression
of an isoform of cyclophilin, cyclophilin D [24]. It is
therefore, tempting to speculate that our observation of
reduced plasma cyclophilin A in our patients taking
metformin is related to metformin action on cyclophilin
A gene expression in monocytes. This hypothesis how-
ever needs scrutiny.
In summary, our study reveals that patients with type 2
diabetes have higher circulating levels of the immunophi-
lin cyclophilin A. Our observations that plasma cyclophi-
lin A is higher in patients with type 2 diabetes irrespective
of whether they have coronary artery disease or not indi-
cates that hyperglycemia has an effect on cyclophilin se-
cretion. Given that cyclophilin is known to be secreted
from monocytes and vascular wall cells in conditions of
oxidative stress such as hyperglycemia, the plasma circu-
lating levels of cyclophilin A in patients with diabetes and
CAD possibly reflects an increased oxidative stress and
proinflammatory status in these conditions. Cyclophilin A
thus needs to be evaluated as a marker of proinflamma-
tory status in type 2 diabetes and possibly a predictor of
early vascular disease through a prospective study in a
large population of diabetic subjects.
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